Mirubedis (Rivaroxaban)

Rivaroxaban works by directly inhibiting factor Xa, a key enzyme in the coagulation cascade. This inhibition blocks the conversion of prothrombin to thrombin, limiting fibrin clot formation while preserving normal platelet function.

The dose of Mirubedis is individualized by the prescribing clinician based on the specific indication, patient renal function, age, weight, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for rivaroxaban in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Mirubedis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Unlike warfarin, which requires routine INR monitoring and has many dietary interactions, rivaroxaban (Mirubedis) provides fixed‑dose oral therapy with predictable anticoagulation and no routine laboratory monitoring. Both drugs reduce clot risk, but rivaroxaban offers a more convenient dosing regimen and fewer food‑drug interactions, though it may have different bleeding risk profiles.

Mirubedis should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and do not use if the packaging is damaged.

Mirubedis is taken orally, usually with food to improve absorption. The tablet should be swallowed whole with a glass of water and not split, crushed, or chewed unless specifically instructed by a healthcare professional.

The most serious risks include major bleeding events such as intracranial hemorrhage, severe gastrointestinal bleeding, and life‑threatening hemorrhage. Patients should be educated to recognize signs of abnormal bleeding and seek immediate medical attention if they occur.

Mirubedis is contraindicated in patients with active pathological bleeding, severe hepatic impairment, or a known hypersensitivity to rivaroxaban or any of its excipients. Caution is also advised for individuals with uncontrolled hypertension, recent major surgery, or those taking other strong anticoagulants.